Form 8-K Intra-Cellular Therapies For: Aug 05
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the FirmAccesswire
- INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the FirmBusiness Wire
- Intra-Cellular Therapies, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ITCI/price-target/">NASDAQ: ITCI</a>) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) ExperienceGlobeNewswire
- Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2022 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
ITCI
Earnings
- 5/10/22 - Beat
ITCI
Sec Filings
- 7/5/22 - Form 4
- 7/5/22 - Form 4
- 6/13/22 - Form 4
- ITCI's page on the SEC website